Employees: 939
Size Shanghai Jiaoda Onlly (600530.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $726M, the 2814th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.91 on 18 Nov 2026.
Performance Over six months the shares fell 25.2%, against -7.0% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 2.3% over the last twelve months (peer median +3.2%); the operating margin is -2.2% (peer median 9.7%).
Valuation It trades at 16.1× enterprise value to sales against a peer median of 2.4× (3rd most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +44 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.0 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥305M | CN¥313M | CN¥324M | CN¥295M | CN¥376M |
| Revenue growth | — | -3% | +10% | -21% | — |
| Gross profit | CN¥125M | CN¥88.6M | CN¥92.6M | CN¥65.5M | CN¥145M |
| EBITDA | n/a | CN¥57.2M | CN¥69.3M | CN¥30.3M | -CN¥287M |
| Net income | -CN¥16.9M | CN¥3.49M | CN¥30.5M | -CN¥35.1M | -CN¥499M |
| Free cash flow | CN¥37.2M | CN¥20.1M | CN¥58.2M | CN¥46.1M | CN¥72.5M |
| Capital expenditure | CN¥3.50M | CN¥2.94M | CN¥5.48M | CN¥9.55M | CN¥25.8M |
| Total debt | CN¥155M | CN¥160M | CN¥158M | CN¥209M | CN¥277M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600530.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +64.2% | -4.1% | highest of 21 |
| 6-month return | -25.2% | -7.0% | 6th lowest of 21 |
| Distance from 52-week high | -31.5% | -34.0% | 10th highest of 21 |
| Revenue growth (TTM) | -2.3% | +3.2% | 8th lowest of 19 |
| Operating margin | -2.2% | 9.7% | 3rd lowest of 19 |
| EV / Sales | 16.1× | 2.4× | 3rd most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 42.7% | -0.7% | most demanding of 13 |
| Growth delivered (Del g) | -0.9% | +1.2% | 3rd lowest of 13 |
| Hurdle (Req g minus delivered) | +43.7 pp | -1.7 pp | most demanding of 13 |
| ROIC minus cost of capital | +0.0 pp | +0.5 pp | 8th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | 16.1× | 42.7% | -0.9% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 3.8× | 5.9% | +11.3% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 3.9× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 2.6× | -4.8% | +6.4% |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 1.1× | -11.8% | +1.9% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | 0.3× | n/a | n/a |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 1.8× | -2.0% | +26.1% |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 0.8× | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | 0.6× | 4.0% | +5.3% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 0.5× | -1.6% | -1.8% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 2.5× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |